Welcome to our dedicated page for INVO BioScience news (Ticker: INVO), a resource for investors and traders seeking the latest updates and insights on INVO BioScience stock.
INVO Bioscience, Inc. (INVO) delivers innovative fertility solutions through its proprietary INVOcell technology and growing network of treatment centers. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, financial performance, and strategic initiatives in assisted reproductive technology.
Access timely updates including earnings reports, regulatory developments, technology partnerships, and clinic expansion announcements. Our curated collection features official press releases alongside verified third-party analysis to support informed decision-making.
Key coverage areas include INVOcell technology updates, clinic network growth, financial disclosures, and industry partnership announcements. Bookmark this page for streamlined monitoring of INVO's progress in making advanced fertility treatments more accessible through medical innovation.
INVO Bioscience announced plans to open a new INVO Center in Kansas City, Missouri, enhancing its expansion strategy aimed at increasing access to fertility care through its INVOcell medical device. The new center aligns with the company's goal to address the significant demand for fertility treatments in areas with limited options, as Kansas City has approximately 33,000 individuals facing infertility issues. Currently operating three INVO Centers, INVO aims to provide efficient and affordable fertility solutions nationwide.
INVO Bioscience, a fertility company listed on NASDAQ under the symbol INVO, will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. The event will feature a webcast presentation available at 11:00am ET on April 4, with replays accessible afterward. The company focuses on affordable fertility care through its innovative INVOcell® medical device and intravaginal culture (IVC) procedure, aiming to enhance accessibility to assisted reproductive technologies globally. Interested parties can arrange meetings with management through Lytham Partners.
INVO Bioscience (Nasdaq: INVO) reported significant growth in 2021, with revenues of $4.2 million, up from $1.0 million in 2020. The increase was largely due to $2.9 million from deferred revenue recognition following the termination of a distribution agreement. The company's gross margin rose to 97%. INVO opened three new clinics and regained full U.S. sales rights for its INVOcell® device, aiming to increase market penetration. Adjusted EBITDA improved to $(2.8) million compared to $(3.7) million in 2020. Cash reserves stood at $5.7 million.
INVO Bioscience, Inc. (NASDAQ: INVO) will release its financial results for Q4 and FY 2021 on March 31, 2022, after market close. The company focuses on improving access to fertility treatments through its innovative device, the INVOcell®. A conference call to discuss these results is scheduled for the same day at 4:30 pm ET. INVO aims to provide affordable solutions for infertility, positioning itself as a leader in Assisted Reproductive Technology (ART).
INVO Bioscience (NASDAQ: INVO) showcased its INVOcell® fertility technology at the PCRS Annual Meeting, held from March 23-27, 2022, in Indian Wells, CA. The event allowed INVO representatives, including Senior VP Chris Myer and sales director Bojan Mitrovic, to engage with U.S. IVF clinics and promote their revolutionary intravaginal culture (IVC) system. The INVOcell® offers an affordable and effective alternative to traditional IVF methods. INVO aims to expand its U.S. presence through dedicated INVO Centers and partnerships with existing clinics.
INVO Bioscience, Inc. (NASDAQ: INVO), a fertility company, announced that Dr. Inger Britt Carlsson, VP of Medical Affairs, will join a roundtable at the 2022 Virtual Growth Conference on March 28 at 3:00 PM. The discussion, titled "Advances in Women's Health: From Clinical to Commercial," will be webcast live and feature other executives from the women's health sector. Attendees can register at the conference page. INVO Bioscience focuses on enhancing access to affordable fertility treatment worldwide through its INVOcell® device, enabling innovative in vivo fertilization methods.
INVO Bioscience (NASDAQ: INVO) is enhancing accessibility to affordable fertility treatments with its INVOcell® technology at its new INVO Center in Birmingham, Alabama. In an inflationary market, the center offers IVC procedures at under $7,000, compared to $12,000-$15,000 for traditional IVF. CEO Steve Shum emphasizes the importance of democratizing fertility options for underserved patients from across 30 states. With comparable pregnancy rates to conventional IVF, INVOcell aims to provide effective solutions that consider financial constraints.
INVO Bioscience, Inc. (NASDAQ: INVO) announced on February 16, 2022, plans to open a new INVO Center in Tampa, Florida. This center aims to provide advanced fertility care using the INVOcell® device, enhancing access for underserved patients. Currently, INVO operates centers in Birmingham, Atlanta, and Monterrey, with another center set to open in San Francisco. CEO Steve Shum emphasized the demographic suitability of Tampa for expanding fertility services. The company is also evaluating opportunities for further growth in other markets.
INVO Bioscience (NASDAQ: INVO) updates its commercialization strategy for the INVOcell medical device, regaining full U.S. rights as of February 1, 2022. This initiative aims to address the unmet needs of the multi-billion dollar fertility market, where over 90% of couples seeking treatment are underserved. The INVOcell device enables intravaginal culture (IVC), allowing natural fertilization and embryo development at an affordable rate. Currently, the company operates three INVO Centers in Birmingham, AL, Atlanta, GA, and Monterey, Mexico, with plans to expand to 20 U.S. cities.
INVO Bioscience, Inc. (NASDAQ: INVO) has regained full U.S. commercialization rights for its INVOcell technology as of February 1, 2022, allowing direct sales to IVF clinics and the establishment of more INVO Centers. The company aims to improve access to fertility treatments, targeting the underserved market where over 90% of couples needing infertility care go without. Key initiatives for 2022 include increasing distribution, driving patient volumes in existing centers, and expanding INVO Centers into more U.S. cities.
